Flu Influenza Vaccine Market
Flu Influenza Vaccine Market Size, Share, and Trends Analysis Report, By Vaccine Type (Quadrivalent and Trivalent), By Technology (Egg-Based and Cell Culture), By Age Group (Pediatric and Adult), By Route of Administration (Injection and Nasal Spray), Forecast (2022 to 2028)
Flu influenza vaccine market is anticipated to grow at a CAGR of 6.9% during the forecast period. Seasonal influenza or flu is an acute respiratory infection caused by influenza viruses and is commonly categorized into 4 types such as types A, B, C, and D. The influenza virus causes regional epidemics and outbreaks, resulting in thousands of mortalities annually. Globally, the flu influenza pandemic is estimated to result in about 3 to 5 million cases of severe illness, and about 290 000 to 650 000 respiratory deaths, as per WHO. In addition, 99% of mortalities in children under 5 years of age with influenza-related lower respiratory tract infections are found in developing countries. Owing to increased prevalence, the development and production of flu influenza vaccines are also surging, leading to market growth. Organizations such as World Health Organization (WHO), the Centers for Disease Control and Prevention (CDC), and other government authorities are creating awareness and assisting the population to fight against the virus by getting vaccinated. To provide maximum protection against diseases, the supply and demand for flu influenza vaccines have surged.
Moreover, an increase in investment by prominent market players and a rise in government support and initiatives such as awareness camps and programs have accelerated the launch of therapeutically effective vaccines which in turn, is driving the global influenza vaccine market growth. However, delays in regulatory approvals for clinical trials may delay the development of vaccines which limits the growth of the market. Major players are investing in R&D facilities to increase their production with advanced technology, which is expected to offer lucrative growth opportunities. For instance, in February 2022, the Seqirus business of CSL Limited invested in a new research and development facility located in Waltham, Mass. The new facility will support the company's growing R&D portfolio, with a focus on a self-amplifying messenger RNA (sa-mRNA) technology platform, the next generation of mRNA technology. The facility will serve as the company's central R&D hub for current and future vaccine design, and collaboration with stakeholders from across the industry and academia.
Segmental Outlook
The global flu influenza vaccine market is segmented based on type, technology, age group, and route of administration. Based on type, the market is segmented into quadrivalent and trivalent. Based on technology, the market is segmented into egg-based and cell culture. Among these, the egg-based technology segment is expected to gain the highest market share owing to the high adoption of this technology in inactivated (killed) and live-attenuated (weakened) vaccines (usually called the nasal spray flu vaccine) development. Besides, the cell culture segment is also projected to witness notable growth owing to its potential for a faster start-up of the flu vaccine manufacturing process. Furthermore, based on age group, it is bifurcated into pediatric and adult. Whereas, based on the route of administration, the market is segmented into injection and nasal spray.
Regional Outlook
Geographically, the global flu influenza vaccine market is classified into four major regions including North America (the US and Canada), Europe (UK, Germany, France, Italy, Spain, and the Rest of Europe), Asia-Pacific (India, China, Japan, South Korea, and Rest of Asia-Pacific), and Rest of the World (Latin America and the Middle East and Africa (MEA)). North America accounted for the largest share in the global influenza vaccine market in 2021 and is expected to retain its dominance during the forecast period. The increased prevalence of influenza in the region’s major economies such as the US, supportive government initiatives and immunization programs, and growth in technological advancements for vaccine development are the major factors assisting in the market growth.
Global Flu Influenza Vaccine Market Growth, By Region 2022-2028
Asia-Pacific Emerge as a Fastest Growing Region in the Market
Geographically, the Asia-Pacific region is expected to emerge as the fastest-growing region during the forecast period. The regional growth is attributed to the increase in awareness programs, rapid growth in healthcare infrastructure, and increasing disposable income levels due to which healthcare spending has increased. The high prevalence of influenza flu in the region’s major economies such as China and India has augmented the production of vaccines. In January 2019, over 608,000 flu cases were reported in mainland China, including 143 mortalities, which was more than the total number of mortalities in 2017. Apart from these, rising government initiatives and their continuous funding for the development of vaccines further propelled the growth of the market in the Asia-Pacific region.
Market Players Outlook
The major players in the global flu influenza vaccine market include AstraZeneca plc, GlaxoSmithKline plc, and Sanofi S.A., among others. The market players are contributing significantly to the growth of the market by the adoption of various strategies including mergers and acquisitions, geographical expansion, partnerships, collaborations, and new product launches, to stay competitive in the market. For instance, in August 2020, BioDiem expanded its business by launching the LAIV vaccine based on BCHT biotechnology in China. BCHT covers the private sector of China for seasonal influenza virus vaccines made using egg-based technology. BCHT got marketing approval for its LAVI vaccine from the Chinese National Medical Products Administration.
The Report Covers
- Market value data analysis of 2021 and forecast to 2028.
- Annualized market revenues ($ million) for each market segment.
- Country-wise analysis of major geographical regions.
- Key companies operating in the global flu influenza vaccine market. Based on the availability of data, information related to pipeline products, and relevant news is also available in the report.
- Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
- Analysis of market-entry and market expansion strategies.
- Competitive strategies by identifying ‘who-stands-where’ in the market.
1. Report Summary
• Current Industry Analysis and Growth Potential Outlook
• Recovery Scenario of Global Flu Influenza Vaccine Industry
1.1. Research Methods and Tools
1.2. Market Breakdown
1.2.1. By Segments
1.2.2. By Region
2. Market Overview and Insights
2.1. Scope of the Report
2.2. Analyst Insight & Current Market Trends
2.2.1. Key Findings
2.2.2. Recommendations
2.2.3. Conclusion
3. Competitive Landscape
3.1. Key Company Analysis
3.1.1. Overview
3.1.2. Financial Analysis
3.1.3. SWOT Analysis
3.1.4. Recent Developments
3.2. Key Strategy Analysis
4. Market Segmentation
4.1. Global Flu Influenza Vaccine Market by Vaccine Type
4.1.1. Quadrivalent
4.1.2. Trivalent
4.2. Global Flu Influenza Vaccine Market by Technology
4.2.1. Egg-Based
4.2.2. Cell Culture
4.3. Global Flu Influenza Vaccine Market by Age Group
4.3.1. Pediatric
4.3.2. Adult
4.4. Global Flu Influenza Vaccine Market by Route of Administration
4.4.1. Injection
4.4.2. Nasal Spray
5. Regional Analysis
5.1. North America
5.1.1. United States
5.1.2. Canada
5.2. Europe
5.2.1. UK
5.2.2. Germany
5.2.3. Italy
5.2.4. Spain
5.2.5. France
5.2.6. Rest of Europe
5.3. Asia-Pacific
5.3.1. China
5.3.2. India
5.3.3. Japan
5.3.4. South Korea
5.3.5. Rest of Asia-Pacific
5.4. Rest of the World
5.4.1. Latin America
5.4.2. Middle East & Africa
6. Company Profiles
6.1. Abbott Laboratories
6.2. AstraZeneca plc
6.3. Biodiem
6.4. CPL Biologicals Pvt. Ltd
6.5. CSL Limited (Seqirus GmbH)
6.6. Emergent BioSolutions
6.7. F. Hoffmann-La Roche Ltd.
6.8. Gamma Vaccines Pty Ltd.
6.9. GlaxoSmithKline plc
6.10. MedImmune LLC (AstraZeneca plc)
6.11. Merck & Co. Inc. (Merck Sharp & Dohme Corp.)
6.12. Mitsubishi Tanabe Pharma Corporation
6.13. Novartis International AG
6.14. Pfizer Inc.
6.15. Sanofi S.A.
6.16. Sinovac Biotech Ltd.
1. GLOBAL FLU INFLUENZA VACCINE MARKET RESEARCH AND ANALYSIS BY VACCINE TYPE, 2021-2028 ($ MILLION)
2. GLOBAL QUADRIVALENT FLU INFLUENZA VACCINE MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
3. GLOBAL TRIVALENT FLU INFLUENZA VACCINE MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
4. GLOBAL FLU INFLUENZA VACCINE MARKET RESEARCH AND ANALYSIS BY TECHNOLOGY, 2021-2028 ($ MILLION)
5. GLOBAL FLU INFLUENZA VACCINE BY EGG-BASED MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
6. GLOBAL FLU INFLUENZA VACCINE BY CELL CULTURE MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
7. GLOBAL FLU INFLUENZA VACCINE MARKET RESEARCH AND ANALYSIS BY AGE GROUP, 2021-2028 ($ MILLION)
8. GLOBAL PEDIATRIC FLU INFLUENZA VACCINE MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
9. GLOBAL ADULT FLU INFLUENZA VACCINE MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
10. GLOBAL FLU INFLUENZA VACCINE MARKET RESEARCH AND ANALYSIS BY ROUTE OF ADMINISTRATION, 2021-2028 ($ MILLION)
11. GLOBAL FLU INFLUENZA VACCINE IN INJECTION MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
12. GLOBAL FLU INFLUENZA VACCINE IN NASAL SPRAY MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
13. GLOBAL FLU INFLUENZA VACCINE MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
14. NORTH AMERICAN FLU INFLUENZA VACCINE MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
15. NORTH AMERICAN FLU INFLUENZA VACCINE MARKET RESEARCH AND ANALYSIS BY VACCINE TYPE, 2021-2028 ($ MILLION)
16. NORTH AMERICAN FLU INFLUENZA VACCINE MARKET RESEARCH AND ANALYSIS BY TECHNOLOGY, 2021-2028 ($ MILLION)
17. NORTH AMERICAN FLU INFLUENZA VACCINE MARKET RESEARCH AND ANALYSIS BY AGE GROUP, 2021-2028 ($ MILLION)
18. NORTH AMERICAN FLU INFLUENZA VACCINE MARKET RESEARCH AND ANALYSIS BY ROUTE OF ADMINISTRATION, 2021-2028 ($ MILLION)
19. EUROPEAN FLU INFLUENZA VACCINE MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
20. EUROPEAN FLU INFLUENZA VACCINE MARKET RESEARCH AND ANALYSIS BY VACCINE TYPE, 2021-2028 ($ MILLION)
21. EUROPEAN FLU INFLUENZA VACCINE MARKET RESEARCH AND ANALYSIS BY TECHNOLOGY, 2021-2028 ($ MILLION)
22. EUROPEAN FLU INFLUENZA VACCINE MARKET RESEARCH AND ANALYSIS BY AGE GROUP, 2021-2028 ($ MILLION)
23. EUROPEAN FLU INFLUENZA VACCINE MARKET RESEARCH AND ANALYSIS BY ROUTE OF ADMINISTRATION, 2021-2028 ($ MILLION)
24. ASIA-PACIFIC FLU INFLUENZA VACCINE MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
25. ASIA-PACIFIC FLU INFLUENZA VACCINE MARKET RESEARCH AND ANALYSIS BY VACCINE TYPE, 2021-2028 ($ MILLION)
26. ASIA-PACIFIC FLU INFLUENZA VACCINE MARKET RESEARCH AND ANALYSIS BY TECHNOLOGY, 2021-2028 ($ MILLION)
27. ASIA-PACIFIC FLU INFLUENZA VACCINE MARKET RESEARCH AND ANALYSIS BY AGE GROUP, 2021-2028 ($ MILLION)
28. ASIA-PACIFIC FLU INFLUENZA VACCINE MARKET RESEARCH AND ANALYSIS BY ROUTE OF ADMINISTRATION, 2021-2028 ($ MILLION)
29. REST OF THE WORLD FLU INFLUENZA VACCINE MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
30. REST OF THE WORLD FLU INFLUENZA VACCINE MARKET RESEARCH AND ANALYSIS BY VACCINE TYPE, 2021-2028 ($ MILLION)
31. REST OF THE WORLD FLU INFLUENZA VACCINE MARKET RESEARCH AND ANALYSIS BY TECHNOLOGY, 2021-2028 ($ MILLION)
32. REST OF THE WORLD FLU INFLUENZA VACCINE MARKET RESEARCH AND ANALYSIS BY AGE GROUP, 2021-2028 ($ MILLION)
33. REST OF THE WORLD FLU INFLUENZA VACCINE MARKET RESEARCH AND ANALYSIS BY ROUTE OF ADMINISTRATION, 2021-2028 ($ MILLION)
1. GLOBAL FLU INFLUENZA VACCINE MARKET SHARE BY VACCINE TYPE, 2021 VS 2028 (%)
2. GLOBAL FLU INFLUENZA VACCINE MARKET SHARE BY TECHNOLOGY, 2021 VS 2028 (%)
3. GLOBAL FLU INFLUENZA VACCINE MARKET SHARE BY AGE GROUP, 2021 VS 2028 (%)
4. GLOBAL FLU INFLUENZA VACCINE MARKET SHARE BY ROUTE OF ADMINISTRATION, 2021 VS 2028 (%)
5. GLOBAL FLU INFLUENZA VACCINE MARKET SHARE BY REGION, 2021 VS 2028 (%)
6. GLOBAL QUADRIVALENT FLU INFLUENZA VACCINE MARKET SHARE BY AGE GROUP, 2021 VS 2028 (%)
7. GLOBAL TRIVALENT FLU INFLUENZA VACCINE MARKET SHARE BY AGE GROUP, 2021 VS 2028 (%)
8. GLOBAL FLU INFLUENZA VACCINE BY EGG-BASED MARKET SHARE BY AGE GROUP, 2021 VS 2028 (%)
9. GLOBAL FLU INFLUENZA VACCINE BY CELL CULTURE MARKET SHARE BY AGE GROUP, 2021 VS 2028 (%)
10. GLOBAL PEDIATRIC FLU INFLUENZA VACCINE MARKET SHARE BY AGE GROUP, 2021 VS 2028 (%)
11. GLOBAL ADULT FLU INFLUENZA VACCINE MARKET SHARE BY AGE GROUP, 2021 VS 2028 (%)
12. GLOBAL FLU INFLUENZA VACCINE IN INJECTION MARKET SHARE BY AGE GROUP, 2021 VS 2028 (%)
13. GLOBAL FLU INFLUENZA VACCINE IN NASAL SPRAY MARKET SHARE BY AGE GROUP, 2021 VS 2028 (%)
14. US FLU INFLUENZA VACCINE MARKET SIZE, 2021-2028 ($ MILLION)
15. CANADA FLU INFLUENZA VACCINE MARKET SIZE, 2021-2028 ($ MILLION)
16. UK FLU INFLUENZA VACCINE MARKET SIZE, 2021-2028 ($ MILLION)
17. FRANCE FLU INFLUENZA VACCINE MARKET SIZE, 2021-2028 ($ MILLION)
18. GERMANY FLU INFLUENZA VACCINE MARKET SIZE, 2021-2028 ($ MILLION)
19. ITALY FLU INFLUENZA VACCINE MARKET SIZE, 2021-2028 ($ MILLION)
20. SPAIN FLU INFLUENZA VACCINE MARKET SIZE, 2021-2028 ($ MILLION)
21. REST OF EUROPE FLU INFLUENZA VACCINE MARKET SIZE, 2021-2028 ($ MILLION)
22. INDIA FLU INFLUENZA VACCINE MARKET SIZE, 2021-2028 ($ MILLION)
23. CHINA FLU INFLUENZA VACCINE MARKET SIZE, 2021-2028 ($ MILLION)
24. JAPAN FLU INFLUENZA VACCINE MARKET SIZE, 2021-2028 ($ MILLION)
25. SOUTH KOREA FLU INFLUENZA VACCINE MARKET SIZE, 2021-2028 ($ MILLION)
26. REST OF ASIA-PACIFIC FLU INFLUENZA VACCINE MARKET SIZE, 2021-2028 ($ MILLION)
27. REST OF THE WORLD FLU INFLUENZA VACCINE MARKET SIZE, 2021-2028 ($ MILLION)
